21 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Francardo V, Geva M, Bez F, Denis Q, Steiner L, Hayden MR, Cenci MA. Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson's Disease. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. PMID 30756361 DOI: 10.1007/s13311-018-00699-9  0.8
2017 Lerner RP, Francardo V, Fujita K, Bimpisidis Z, Jourdain VA, Tang CC, Dewey SL, Chaly T, Cenci MA, Eidelberg D. Levodopa-induced abnormal involuntary movements correlate with altered permeability of the blood-brain-barrier in the basal ganglia. Scientific Reports. 7: 16005. PMID 29167476 DOI: 10.1038/s41598-017-16228-1  0.8
2017 Francardo V, Schmitz Y, Sulzer D, Angela Cenci M. Neuroprotection and neurorestoration as experimental therapeutics for Parkinson's disease. Experimental Neurology. PMID 28988910 DOI: 10.1016/j.expneurol.2017.10.001  0.68
2016 Bez F, Francardo V, Cenci MA. Dramatic differences in susceptibility to L-DOPA-induced dyskinesia between mice that are aged before or after a nigrostriatal dopamine lesion. Neurobiology of Disease. PMID 27312773 DOI: 10.1016/j.nbd.2016.06.005  0.8
2016 Shen W, Plotkin JL, Francardo V, Ko WK, Xie Z, Li Q, Fieblinger T, Wess J, Neubig RR, Lindsley CW, Conn PJ, Greengard P, Bezard E, Cenci MA, Surmeier DJ. M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia. Neuron. 90: 1139. PMID 27253449 DOI: 10.1016/j.neuron.2016.05.017  0.8
2016 Marongiu R, Arango-Lievano M, Francardo V, Morgenstern P, Zhang X, Cenci MA, Svenningsson P, Greengard P, Kaplitt MG. Gene therapy blockade of dorsal striatal p11 improves motor function and dyskinesia in parkinsonian mice. Proceedings of the National Academy of Sciences of the United States of America. PMID 26787858 DOI: 10.1073/pnas.1524387113  0.68
2015 Shen W, Plotkin JL, Francardo V, Ko WK, Xie Z, Li Q, Fieblinger T, Wess J, Neubig RR, Lindsley CW, Conn PJ, Greengard P, Bezard E, Cenci MA, Surmeier DJ. M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia. Neuron. 88: 762-773. PMID 26590347 DOI: 10.1016/j.neuron.2015.10.039  0.68
2015 Janelidze S, Lindqvist D, Francardo V, Hall S, Zetterberg H, Blennow K, Adler CH, Beach TG, Serrano GE, van Westen D, Londos E, Cenci MA, Hansson O. Increased CSF biomarkers of angiogenesis in Parkinson disease. Neurology. PMID 26511451 DOI: 10.1212/WNL.0000000000002151  0.68
2015 Cenci MA, Francardo V, O'Sullivan SS, Lindgren HS. Rodent models of impulsive-compulsive behaviors in Parkinson's disease: How far have we reached? Neurobiology of Disease. 82: 561-73. PMID 26325219 DOI: 10.1016/j.nbd.2015.08.026  0.68
2015 Bastide MF, Meissner WG, Picconi B, Fasano S, Fernagut PO, Feyder M, Francardo V, Alcacer C, Ding Y, Brambilla R, Fisone G, Jon Stoessl A, Bourdenx M, Engeln M, Navailles S, et al. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. Progress in Neurobiology. PMID 26209473 DOI: 10.1016/j.pneurobio.2015.07.002  0.68
2014 Francardo V. Sigma-1 receptor: a potential new target for Parkinson's disease? Neural Regeneration Research. 9: 1882-3. PMID 25558236 DOI: 10.4103/1673-5374.145351  0.68
2014 Francardo V, Bez F, Wieloch T, Nissbrandt H, Ruscher K, Cenci MA. Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism. Brain : a Journal of Neurology. 137: 1998-2014. PMID 24755275 DOI: 10.1093/brain/awu107  0.68
2014 Heiman M, Heilbut A, Francardo V, Kulicke R, Fenster RJ, Kolaczyk ED, Mesirov JP, Surmeier DJ, Cenci MA, Greengard P. Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia. Proceedings of the National Academy of Sciences of the United States of America. 111: 4578-83. PMID 24599591 DOI: 10.1073/pnas.1401819111  0.68
2014 Francardo V, Cenci MA. Investigating the molecular mechanisms of L-DOPA-induced dyskinesia in the mouse. Parkinsonism & Related Disorders. 20: S20-2. PMID 24262181 DOI: 10.1016/S1353-8020(13)70008-7  0.68
2014 Francardo V, Iderberg H, Lindgren H, Angela Cenci M. Rodent Models of Treatment-Related Complications in Parkinson Disease Movement Disorders: Genetics and Models: Second Edition. 373-386. DOI: 10.1016/B978-0-12-405195-9.00022-6  0.68
2014 Francardo V, Cenci MA. Preclinical models of levodopa-induced dyskinesia Levodopa-Induced Dyskinesia in Parkinson's Disease. 335-353. DOI: 10.1007/978-1-4471-6503-3_18  0.68
2012 Lindgren N, Francardo V, Quintino L, Lundberg C, Cenci MA. A model of GDNF gene therapy in mice with 6-Hydroxydopamine lesions: time course of Neurorestorative effects and ERK1/2 activation. Journal of Parkinson's Disease. 2: 333-48. PMID 23938263 DOI: 10.3233/JPD-012146  0.68
2012 Iderberg H, Francardo V, Pioli EY. Animal models of l-DOPA-induced dyskinesia: An update on the current options Neuroscience. 211: 13-27. PMID 22465440 DOI: 10.1016/j.neuroscience.2012.03.023  0.68
2011 Ohlin KE, Francardo V, Lindgren HS, Sillivan SE, O'Sullivan SS, Luksik AS, Vassoler FM, Lees AJ, Konradi C, Cenci MA. Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia. Brain : a Journal of Neurology. 134: 2339-57. PMID 21771855 DOI: 10.1093/brain/awr165  0.68
2011 Francardo V, Recchia A, Popovic N, Andersson D, Nissbrandt H, Cenci MA. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease. Neurobiology of Disease. 42: 327-40. PMID 21310234 DOI: 10.1016/j.nbd.2011.01.024  0.68
2010 Fasano S, Bezard E, D'Antoni A, Francardo V, Indrigo M, Qin L, Doveró S, Cerovic M, Cenci MA, Brambilla R. Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia. Proceedings of the National Academy of Sciences of the United States of America. 107: 21824-9. PMID 21115823 DOI: 10.1073/pnas.1012071107  0.68
Show low-probability matches.